Co-Diagnostics Inc New (CODX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Cass and I will be your conference operator today. At this time, I would like to welcome everyone to the co-diagnostics first quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, simply press star 1 again. I would now like to turn the call over to Andrew Benson, Head of Investor Relations. Please go ahead. Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from CoDiagnostics, we have Dwight Egan, Chief Executive Officer, and Brian Brown, Chief Financial Officer. Earlier today, CoDiagnostics released financial results from the first quarter and in March 31, 2025. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A. Before we begin, we would like to inform the listeners that certain statements made by CoDiagnostics during this call, which are not historical facts, are forward-looking statements. This includes statements concerning the company's CoDx PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale. in addition to diagnostic test developments and timing for commencement of clinical evaluations. Actual outcomes and results may differ materially from what is expressed or implied in any statement. Important factors which could cause actual results to differ materially from those in these forward-looking statements a...